Detailed clinical manifestations at onset and prognosis of neonatal-onset Denys–Drash syndrome and congenital nephrotic syndrome of the Finnish type

Kentaro Nishi(National Center For Child Health and Development), Kenji Ishikura(Kitasato University), Masao Ogura(Hokkaido University Hospital), Riku Hamada, Yuko Hamasaki(Toho University), Koichi Nakanishi(University of the Ryukyus), Tomohiro Inoguchi(Tokyo Metropolitan Children's Medical Center), Shuichi Ito(Yokohama City University), Hiroshi Hataya(Japanese Society for Dialysis Therapy), Koichi Kamei(National Center For Child Health and Development), Mai Sato(Kyoto University), Takako Yoshioka(National Center For Child Health and Development), Kentaro Ogata(National Defense Medical College), Kandai Nozu(Kobe Children's Hospital)
Clinical and Experimental Nephrology
April 8, 2019
10.1007/s10157-019-01732-7
Cited by 24

Related Papers

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial
|The Lancet|2014|450
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|278
Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease
|Clinical and Experimental Nephrology|2013|267
Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies
|Pediatric Nephrology|2021|149
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment
|Kidney International|2014|135